Purdue mulls bankruptcy as mountain of litigation looms

5 March 2019
purduebig

Embattled Oxycontin (oxycodone) manufacturer Purdue Pharma is reportedly exploring the option of filing for bankruptcy as legal challenges mount over the firm’s marketing practices.

Following on from a disastrous epidemic of opioid addiction in the USA, multiple lawsuits have been launched by US state and local government bodies against opioid manufacturers and distributors.

Purdue, which is alleged to have downplayed the risk of addiction posed by its products, faces more than 1,600 plaintiffs in a federal class action suit in Ohio.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical